Novel Therapeutic Classes in Lung Cancer
This special issue belongs to the section "Cancer Therapy".
Special Issue Information
Dear Colleagues,
Lung cancer remains the leading cause of cancer-related mortality worldwide despite substantial progress in molecularly targeted therapies and immunotherapy. The therapeutic landscape continues to evolve rapidly with the development of novel therapeutic classes, innovative combination strategies and emerging treatment paradigms that have the potential to further improve outcomes across both non-small-cell and small-cell lung cancer.
This Special Issue aims to provide a comprehensive and contemporary overview of emerging therapeutic advances in lung cancer, spanning basic, translational and clinical research. We welcome original research articles, state of the art reviews and perspective pieces addressing new drug classes, rational combination strategies, resistance mechanisms, biomarker development, precision oncology approaches and real-world implementation challenges.
In addition to currently established and emerging therapeutic modalities, we strongly encourage submissions exploring innovative treatment concepts, novel biological pathways and future therapeutic platforms that may shape the next generation of lung cancer care. This issue seeks to provide a broad platform for clinically meaningful innovation and to define future directions in lung cancer therapeutics. This Special Issue welcomes reviews as well as original research articles by 31st December 2026.
Dr. Rajat Thawani
Dr. Rohit Singh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small-cell lung cancer
- small-cell lung cancer
- antibody–drug conjugates
- bispecific antibodies
- resistance mechanisms
- precision oncology
- immunotherapy combinations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

